Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05457283
Registration number
NCT05457283
Ethics application status
Date submitted
11/07/2022
Date registered
13/07/2022
Date last updated
19/07/2024
Titles & IDs
Public title
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Query!
Scientific title
An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Query!
Secondary ID [1]
0
0
2023-504885-50-00
Query!
Secondary ID [2]
0
0
20186
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
FIONA OLE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Condition category
Condition code
Renal and Urogenital
0
0
0
0
Query!
Kidney disease
Query!
Renal and Urogenital
0
0
0
0
Query!
Other renal and urogenital disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Finerenone (Kerendia, BAY94-8862)
Experimental: Finerenone Open-Label safety Extension - Participants will receive finerenone treatment.
Treatment: Drugs: Finerenone (Kerendia, BAY94-8862)
Finerenone in different doses, treatment duration will be 540 ±7 days.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of participants with treatment emergent adverse event (TEAEs)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to 550 days
Query!
Primary outcome [2]
0
0
Change in serum potassium levels from baseline to Day 540±7
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Up to 547 days
Query!
Primary outcome [3]
0
0
Change in systolic blood pressure (SBP) from baseline to Day 540±7
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Up to 547 days
Query!
Secondary outcome [1]
0
0
Change in urinary protein-to-creatinine ratio (UPCR) from baseline to Day 540±7
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to 547 days
Query!
Secondary outcome [2]
0
0
Change in urinary albumin-to-creatinine ratio (UACR) from baseline to Day 540±7
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Up to 547 days
Query!
Secondary outcome [3]
0
0
Change in estimated glomerular filtration rate (eGFR) from baseline to Day 540±7
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Up to 547 days
Query!
Eligibility
Key inclusion criteria
* Participants must be =1 year to 18 years of age, at the time of signing the informed consent/assent.
* Prior participation in the finerenone Phase 3 study FIONA (19920) and not permanently discontinued from treatment by the end of treatment (EoT) visit in FIONA.
* Participants must have a clinical diagnosis of chronic kidney disease (CKD) at Visit 1 which is defined as
* CKD stages 1-3 (estimated glomerular filtration rate [eGFR] =30 mL/min/1.73m^2) for children =1 year to <19 years of age at FIONA EoT and at Visit 1
* Treated with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at optimized doses defined as maximally tolerable doses within the recommended dose range according to guidelines on blood pressure (BP) management, unchanged for at least 30 days prior to Visit 1.
* K+ =5.0 mmol/L for children =2 years of age at both FIONA EoT and Visit 1, and =5.3 mmol/L for children <2 years of age at both FIONA EoT and Visit 1
* Participants who have reached legal age of consent: Capable of giving signed informed consent.
* Participant is able to receive enteral feeding (solid food, bottle or cup fed, feeding through nasogastric or gastric feeding tubes) with or without breastfeeding.
Query!
Minimum age
1
Year
Query!
Query!
Maximum age
18
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Planned urological surgery expected to influence renal function
* Patients who are candidates for renal transplantation, i.e., a kidney transplantation scheduled within the study time frame
* Systemic hypertension Stage 2 defined according to institutional guidelines on BP management at Visit 1.
* Systemic hypotension defined as symptomatic hypotension or a mean systolic BP below the 5th percentile for age, sex and height but no lower than 80 mmHg for participants <18 years and symptomatic hypotension or a mean systolic blood pressure (SBP) <90 mmHg in participants =18 years at Visit 1.
* Known hypersensitivity to the study treatment (active substance or excipients)
* Severe hepatic insufficiency defined by e.g. Child-Pugh C or analogous scores.
* Participants using rituximab, cyclophosphamide, abatacept, or intravenous glucocorticoids
* Concomitant therapy with a mineralocorticoid receptor antagonist (MRA)(eplerenone, spironolactone, esaxerenone, canrenone), any renin inhibitor (aliskiren, enalkiren, remikiren), any sodium-glucose co-transporter-2 (SGLT2) inhibitor (SGLT2i), sacubitril/valsartan combination (ARNI), or potassium-sparing diuretic (amiloride, triamterene)
* Concomitant therapy with both ACEI and ARBs together
* Concomitant therapy with strong cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors, moderate or strong CYP3A4 inducers
* Previous assignment to treatment during this study
* Simultaneous participation in another interventional clinical study (e.g., Phase 1 to 4 clinical studies).
* Any suspected (serious) adverse event related to study intervention which led to permanent discontinuation during the FIONA study.
* Pregnant or breastfeeding or intention to become pregnant during the study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
8/11/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
10/09/2028
Query!
Actual
Query!
Sample size
Target
100
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Query!
Recruitment hospital [1]
0
0
Queensland Children's Hospital - South Brisbane
Query!
Recruitment hospital [2]
0
0
Monash Children's Hospital - Clayton
Query!
Recruitment hospital [3]
0
0
Royal Children's Hospital Melbourne - Parkville
Query!
Recruitment hospital [4]
0
0
Many Locations - Multiple Locations
Query!
Recruitment postcode(s) [1]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [2]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [3]
0
0
3052 - Parkville
Query!
Recruitment postcode(s) [4]
0
0
- Multiple Locations
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
District of Columbia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Iowa
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maryland
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Missouri
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Ohio
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Oregon
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Texas
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Utah
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Washington
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Buenos Aires
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Ciudad Auton. De Buenos Aires
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Provincia De San Luis
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Provincia De Santa Fe
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Multiple Locations
Query!
Country [21]
0
0
Austria
Query!
State/province [21]
0
0
Oberösterreich
Query!
Country [22]
0
0
Austria
Query!
State/province [22]
0
0
Steiermark
Query!
Country [23]
0
0
Austria
Query!
State/province [23]
0
0
Multiple Locations
Query!
Country [24]
0
0
Austria
Query!
State/province [24]
0
0
Salzburg
Query!
Country [25]
0
0
Austria
Query!
State/province [25]
0
0
Wien
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Bruxelles - Brussel
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Gent
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Leuven
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Liège
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Multiple Locations
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Alberta
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Ontario
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Quebec
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Multiple Locations
Query!
Country [35]
0
0
Czechia
Query!
State/province [35]
0
0
Multiple Locations
Query!
Country [36]
0
0
Czechia
Query!
State/province [36]
0
0
Praha 2
Query!
Country [37]
0
0
Czechia
Query!
State/province [37]
0
0
Praha 5
Query!
Country [38]
0
0
Denmark
Query!
State/province [38]
0
0
Copenhagen
Query!
Country [39]
0
0
Denmark
Query!
State/province [39]
0
0
Multiple Locations
Query!
Country [40]
0
0
Denmark
Query!
State/province [40]
0
0
Odense C
Query!
Country [41]
0
0
Denmark
Query!
State/province [41]
0
0
Århus N
Query!
Country [42]
0
0
Finland
Query!
State/province [42]
0
0
Helsinki
Query!
Country [43]
0
0
Finland
Query!
State/province [43]
0
0
Multiple Locations
Query!
Country [44]
0
0
Finland
Query!
State/province [44]
0
0
Tampere
Query!
Country [45]
0
0
Finland
Query!
State/province [45]
0
0
Turku
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
BORDEAUX cedex
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Bron
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Montpellier
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Multiple Locations
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Paris
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Strasbourg
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
TOULOUSE Cedex 9
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Baden-Württemberg
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Bayern
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Niedersachsen
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Nordrhein-Westfalen
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Berlin
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Hamburg
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Multiple Locations
Query!
Country [60]
0
0
Greece
Query!
State/province [60]
0
0
Athens
Query!
Country [61]
0
0
Greece
Query!
State/province [61]
0
0
Heraklion
Query!
Country [62]
0
0
Greece
Query!
State/province [62]
0
0
Ioannina
Query!
Country [63]
0
0
Greece
Query!
State/province [63]
0
0
Multiple Locations
Query!
Country [64]
0
0
Greece
Query!
State/province [64]
0
0
Thessaloniki
Query!
Country [65]
0
0
Hungary
Query!
State/province [65]
0
0
Budapest
Query!
Country [66]
0
0
Hungary
Query!
State/province [66]
0
0
Debrecen
Query!
Country [67]
0
0
Hungary
Query!
State/province [67]
0
0
Multiple Locations
Query!
Country [68]
0
0
Hungary
Query!
State/province [68]
0
0
Pecs
Query!
Country [69]
0
0
Hungary
Query!
State/province [69]
0
0
Szeged
Query!
Country [70]
0
0
Israel
Query!
State/province [70]
0
0
Beer Sheva
Query!
Country [71]
0
0
Israel
Query!
State/province [71]
0
0
Jerusalem
Query!
Country [72]
0
0
Israel
Query!
State/province [72]
0
0
Multiple Locations
Query!
Country [73]
0
0
Israel
Query!
State/province [73]
0
0
Nahariya
Query!
Country [74]
0
0
Israel
Query!
State/province [74]
0
0
Petach Tikva
Query!
Country [75]
0
0
Israel
Query!
State/province [75]
0
0
Tel Aviv
Query!
Country [76]
0
0
Italy
Query!
State/province [76]
0
0
Emilia-Romagna
Query!
Country [77]
0
0
Italy
Query!
State/province [77]
0
0
Lazio
Query!
Country [78]
0
0
Italy
Query!
State/province [78]
0
0
Liguria
Query!
Country [79]
0
0
Italy
Query!
State/province [79]
0
0
Lombardia
Query!
Country [80]
0
0
Italy
Query!
State/province [80]
0
0
Firenze
Query!
Country [81]
0
0
Italy
Query!
State/province [81]
0
0
Multiple Locations
Query!
Country [82]
0
0
Italy
Query!
State/province [82]
0
0
Torino
Query!
Country [83]
0
0
Korea, Republic of
Query!
State/province [83]
0
0
Daegu Gwang''yeogsi
Query!
Country [84]
0
0
Korea, Republic of
Query!
State/province [84]
0
0
Gyeonggido
Query!
Country [85]
0
0
Korea, Republic of
Query!
State/province [85]
0
0
Gyeongsangnamdo
Query!
Country [86]
0
0
Korea, Republic of
Query!
State/province [86]
0
0
Seoul Teugbyeolsi
Query!
Country [87]
0
0
Korea, Republic of
Query!
State/province [87]
0
0
Multiple Locations
Query!
Country [88]
0
0
Korea, Republic of
Query!
State/province [88]
0
0
Seoul
Query!
Country [89]
0
0
Lithuania
Query!
State/province [89]
0
0
Kaunas
Query!
Country [90]
0
0
Lithuania
Query!
State/province [90]
0
0
Klaipeda
Query!
Country [91]
0
0
Lithuania
Query!
State/province [91]
0
0
Multiple Locations
Query!
Country [92]
0
0
Lithuania
Query!
State/province [92]
0
0
Vilnius
Query!
Country [93]
0
0
Netherlands
Query!
State/province [93]
0
0
Groningen
Query!
Country [94]
0
0
Netherlands
Query!
State/province [94]
0
0
Multiple Locations
Query!
Country [95]
0
0
Netherlands
Query!
State/province [95]
0
0
Utrecht
Query!
Country [96]
0
0
Poland
Query!
State/province [96]
0
0
Bialystok
Query!
Country [97]
0
0
Poland
Query!
State/province [97]
0
0
Gdansk
Query!
Country [98]
0
0
Poland
Query!
State/province [98]
0
0
Krakow
Query!
Country [99]
0
0
Poland
Query!
State/province [99]
0
0
Lodz
Query!
Country [100]
0
0
Poland
Query!
State/province [100]
0
0
Multiple Locations
Query!
Country [101]
0
0
Poland
Query!
State/province [101]
0
0
Warszawa
Query!
Country [102]
0
0
Poland
Query!
State/province [102]
0
0
Wroclaw
Query!
Country [103]
0
0
Portugal
Query!
State/province [103]
0
0
Lisboa
Query!
Country [104]
0
0
Portugal
Query!
State/province [104]
0
0
Braga
Query!
Country [105]
0
0
Portugal
Query!
State/province [105]
0
0
Multiple Locations
Query!
Country [106]
0
0
Portugal
Query!
State/province [106]
0
0
Porto
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
Barcelona
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Madrid
Query!
Country [109]
0
0
Spain
Query!
State/province [109]
0
0
Multiple Locations
Query!
Country [110]
0
0
Spain
Query!
State/province [110]
0
0
Málaga
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
Sevilla
Query!
Country [112]
0
0
Sweden
Query!
State/province [112]
0
0
Lund
Query!
Country [113]
0
0
Sweden
Query!
State/province [113]
0
0
Multiple Locations
Query!
Country [114]
0
0
Sweden
Query!
State/province [114]
0
0
Stockholm
Query!
Country [115]
0
0
Sweden
Query!
State/province [115]
0
0
Uppsala
Query!
Country [116]
0
0
Switzerland
Query!
State/province [116]
0
0
Basel-Stadt
Query!
Country [117]
0
0
Switzerland
Query!
State/province [117]
0
0
Vaud
Query!
Country [118]
0
0
Switzerland
Query!
State/province [118]
0
0
Multiple Locations
Query!
Country [119]
0
0
Turkey
Query!
State/province [119]
0
0
Ankara
Query!
Country [120]
0
0
Turkey
Query!
State/province [120]
0
0
Istanbul
Query!
Country [121]
0
0
Turkey
Query!
State/province [121]
0
0
Multiple Locations
Query!
Country [122]
0
0
United Kingdom
Query!
State/province [122]
0
0
Stratchclyde
Query!
Country [123]
0
0
United Kingdom
Query!
State/province [123]
0
0
West Midlands
Query!
Country [124]
0
0
United Kingdom
Query!
State/province [124]
0
0
London
Query!
Country [125]
0
0
United Kingdom
Query!
State/province [125]
0
0
Manchester
Query!
Country [126]
0
0
United Kingdom
Query!
State/province [126]
0
0
Multiple Locations
Query!
Country [127]
0
0
United Kingdom
Query!
State/province [127]
0
0
Nottingham
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bayer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine. The kidneys filter waste and fluid from the blood to form urine. In children with CKD, the kidney´s filters do not work as well as they should. This can lead to accumulation of waste and fluid in the body and proteinuria. CKD can lead to other medical problems, such as high blood pressure, also known as hypertension. Vice versa, hypertension and proteinuria can also contribute to worsening of CKD. Therefore, the treatment of CKD aims to control blood pressure and proteinuria. There are treatments available for doctors to prescribe to children with CKD and hypertension and/or proteinuria. These include "angiotensin-converting enzyme inhibitors" (ACEI) and "angiotensin receptor blockers" (ARB). Both ACEI and ARB can help improve kidney function by reducing the activity of the renin-angiotensin-aldosterone system (RAAS). The RAAS is a system that works with the kidneys to control blood pressure and the balance of fluid and electrolytes in the blood. In people with CKD, the RAAS is often too active, which can impair the ability of the kidneys to work properly and cause hypertension and proteinuria. However, ACEI or ARB treatment alone does not work for all patients with CKD as they only target the angiotensin part of the renin-angiotensin-aldosterone system. The study treatment, finerenone, is expected to help control RAAS overactivation together with an ACEI or ARB. So, the researchers in this study want to learn more about whether finerenone given in addition to either an ACEI or ARB can help their kidney function. The main purpose of this study is to learn how safe the treatment is when used of finerenone in addition to an ACEI or ARB in long-term. To see how safe the treatment is, the study team will collect information on medical problems which are also known as "treatment emergent adverse events" (TEAEs). And they will also collect levels of an electrolyte called potassium in the blood by taking blood samples, and measure blood pressure during the study. The secondary purpose of this study is to learn how well long-term use of finerenone can reduce the amount of protein in the participants' urine and benefit kidney function when taken with standard of care. To see how the treatment works, the study team will collect participants' urine samples to assess urinary albumin-to-creatinine ratio (UACR) and urinary protein-to-creatinine ratio (UPCR), which are important assessments for calculating the level of protein in the urine. Researchers will also collect blood samples to analyze serum creatinine and calculate estimated glomerular filtration rate (eGFR). A significant decline in eGFR indicates worsening kidney function. The study will include participants who had previously participated in FIONA study (NCT05196035). The participants will be aged from 1 year up to 18 years. The participants will be in the study for approximately 19 months. They will take study treatment for up to 18 months and will be follow up for 1 month. During this period, at least 12 visits are planned for patients who newly start finerenone, and at least 8 visits for patients who already received finerenone. In the visit, the study team will: * have their blood pressure, heart rate, temperature, height and weight measured * have blood and urine samples taken * have physical examinations * have their heart examined by an electrocardiogram and echocardiography (a sonogram of the heart) * answer questions about their medication and whether they have any adverse events, or have their parents or guardian's answer * answer questions about how they are feeling, or have their parents or guardian's answer * answer question about how they like the study medication, or have their parents or guardian's answer The doctors will keep track of any adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The doctors will check the participants' health about 30 days after the participants take their last treatment.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05457283
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Bayer Clinical Trials Contact
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
(+)1-888-84 22937
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05457283
Download to PDF